W.L. Gore put up a $10 million convertible note for ViaCyte and the Type I diabetes treatment they’re working on.
Last year the companies inked a deal to work on the synthetic pancreas ViaCyte is developing. The San Diego-based company’s Encaptra device is designed to be seeded with stem cells engineered to become pancreatic cells and implanted under the skin.
Get the full story at our sister site, Drug Delivery Business News.
The post Gore adds $10m to ViaCyte investment appeared first on MassDevice.
from MassDevice https://ift.tt/2QXfy7l
Cap comentari:
Publica un comentari a l'entrada